IPSEN – Buy-back program – Art 5 of MAR – Week 42 – 2023
- 24 October 2023 - 1 mins read
Aggregated presentation by day and by market
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 16/10/2023 | FR0010259150 | 258 | 117.59 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 16/10/2023 | FR0010259150 | 1,442 | 117.86 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/10/2023 | FR0010259150 | 57 | 119.40 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/10/2023 | FR0010259150 | 1,502 | 118.56 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/10/2023 | FR0010259150 | 58 | 118.10 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/10/2023 | FR0010259150 | 1,742 | 118.33 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 19/10/2023 | FR0010259150 | 4 | 117.10 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 19/10/2023 | FR0010259150 | 44 | 117.10 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 19/10/2023 | FR0010259150 | 4 | 117.10 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 19/10/2023 | FR0010259150 | 1,698 | 116.73 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/10/2023 | FR0010259150 | 56 | 113.76 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/10/2023 | FR0010259150 | 1,694 | 113.82 | XPAR |
| * Two-digit rounding after the decimal | TOTAL | 8,559 | 117.03 | |||
Attachment
11 July 2024
6 mins read
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
09 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024
1 mins read
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
08 July 2024
1 mins read
Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024
9 mins read
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
25 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
18 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
11 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
10 June 2024
12 mins read